Comparison of the Impact of Xanthohumol and Phenethyl Isothiocyanate and Their Combination on Nrf2 and NF-κB Pathways in HepG2 Cells In Vitro and Tumor Burden In Vivo

Nutrients. 2021 Aug 28;13(9):3000. doi: 10.3390/nu13093000.

Abstract

Background: Increasing evidence suggests that combinations of phytochemicals are more efficient than single components in the modulation of signaling pathways involved in cancer development. In this study, the impact of phenethyl isothiocyanate (PEITC), indole-3-carbinol (I3C), xanthohumol, (X), and resveratrol (RES) and their combinations on the activation and expression of Nrf2 and NF-κB in human hepatocytes and HCC cells were evaluated. Methods: THLE-2 and HepG2 cells were exposed to single phytochemicals and their combinations for 24 h. The activation of Nrf2 and NF-κB, expression of their target genes, and effect on cells survival were assessed. The tumor burden was evaluated in mice carrying xenografts. Results: All phytochemicals enhanced the activation and expression of Nrf2 and its target genes SOD and NQO1 in HepG2 cells. The increased expression of NQO1 (~90%) was associated with increased ROS generation. X + PEITC downregulated NF-κB activation reducing binding of its active subunits to DNA resulting in diminished COX-2 expression. In contrast to single phytochemicals, X + PEITC induced apoptosis. Moderate reduction of tumor burden in mice carrying xenografts following X and PEITC or their combination was observed. Conclusions: Since Nrf2 is overexpressed in HCC its reduced activation together with diminished level of NF-κB by X + PEITC may be considered as a strategy to support conventional HCC therapy.

Keywords: HepG2 and THLE-2 cells; NF-κB; Nrf2; mice xenograft model; phytochemicals combinations.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Anticarcinogenic Agents / pharmacology*
  • Anticarcinogenic Agents / therapeutic use
  • Apoptosis
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Down-Regulation
  • Drug Combinations
  • Flavonoids / pharmacology*
  • Flavonoids / therapeutic use
  • Hep G2 Cells
  • Hepatoblastoma / drug therapy
  • Hepatoblastoma / metabolism*
  • Humans
  • Isothiocyanates / pharmacology*
  • Isothiocyanates / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / metabolism*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • NAD(P)H Dehydrogenase (Quinone) / metabolism
  • NF-E2-Related Factor 2 / metabolism*
  • NF-kappa B / metabolism*
  • Propiophenones / pharmacology*
  • Propiophenones / therapeutic use
  • Signal Transduction
  • Superoxide Dismutase / metabolism
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Substances

  • Anticarcinogenic Agents
  • Cyclooxygenase 2 Inhibitors
  • Drug Combinations
  • Flavonoids
  • Isothiocyanates
  • NF-E2-Related Factor 2
  • NF-kappa B
  • NFE2L2 protein, human
  • Propiophenones
  • phenethyl isothiocyanate
  • Superoxide Dismutase
  • NAD(P)H Dehydrogenase (Quinone)
  • NQO1 protein, human
  • xanthohumol